Bharat Biotech, a Covid vaccine manufacturer, has asked the union government to include their intranasal COVID vaccination, iNCOVACC, in the CoWIN portal. They requested to include it in the CoWin portal to enable the recipients to get vaccination certificates. The sources from the company stated that the manufacturers are holding discussions with "potential partners" to manufacture and distribute the intranasal vaccine globally.

The CoWin portal currently lists Bharat Biotech′s Covaxin, Serum Institute′s Covishield and Covovax, Russian Sputnik V, and Biological E Ltd.′s Corbevax. On September 6, the vaccine makers announced that iNCOVACC (BBV154) has received approval from the Drugs Controller General of India for restricted use in emergencies for ages 18 and above.

iNCOVACC (BBV154) was developed in partnership with Washington University in St. Louis, which designed, developed, and evaluated the recombinant adenoviral vector construct in pre-clinical studies for efficacy. 

(Source: https://www.thehindu.com/sci-tech/health/bharat-biotech-urges-centre-to-include-its-intranasal-covid-vaccine-in-cowin-portal/article66250858.ece )